Background Since the release of the first global hepatitis elimination targets in 2016, and
until the COVID-19 pandemic started in early 2020, many countries and territories were …

In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …

Abstract Background and Aims Macrophages are prominent components of solid tumors and
exhibit distinct functions in different tumor microenvironments. Exosomes are emerging as …

Following the discovery of hepatitis C virus (HCV) in 1989, 3 decades of basic, translational,
and clinical research culminated in the development of direct-acting antiviral (DAA) therapy …

Background and aim Hepatitis C virus infection can lead to an enormous health burden
worldwide. Investigating the changes in HCV-related burden between different countries …

Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality
rates in humans of up to 90%. MARV has been identified as a category A bioterrorism agent …

Background COH04S1, a synthetic attenuated modified vaccinia virus Ankara vector co-
expressing SARS-CoV-2 spike and nucleocapsid antigens, was tested for safety and …

Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but
most patients can now expect to achieve a sustained virological response (SVR). With direct …

Acute hepatitis C virus (HCV) infection is a global health concern with substantial
geographical variation in the incidence rate. People who have received unsafe medical …